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It has been estimated that 50–70% of human 
conceptions fail and that 1–3% of women in 
the United States suff  er recurrent miscarriages 
(1). Moreover, intrauterine growth restriction 
(IUGR) occurs in up to 10% of infants born in 
the United States (2), and growth-restricted 
  fetuses have higher mortality and morbidity 
rates than fetuses with weights greater than the 
10th percentile. Although the insult to the fetus 
  occurs in utero, the deleterious infl  uence  of 
IUGR contributes to long-term developmen-
tal delay, and a suboptimal intrauterine envi-
ronment has been linked to metabolic disorders 
during adult life, including coronary artery dis-
ease, hypertension, hyperlipidemia, and insulin 
resistance (3).
Although the causes of recurrent miscar-
riages and IUGR are poorly understood, an im-
mune mechanism involving inappropriate and 
subsequently injurious recognition of the con-
ceptus by the mother’s immune system has been 
proposed. This misdirected immune response 
to fetus, placenta, or both could yield a wide 
range of phenotypes, including miscarriages 
early in pregnancy and IUGR later in preg-
nancy.   Pregnancy constitutes a major challenge 
to the   maternal immune system because it re-
quires tolerance of fetal alloantigens encoded by 
paternal genes. Local factors at the maternal–  fetal 
interface are required to maintain such   tolerance 
and assure normal development of semiallogenic 
concepti (4). The fetus is protected from mater-
nal immune responses through mechanisms such 
as expression of HLA-G (5), inhibitory T cell 
costimulatory molecules (6), and complement 
regulatory proteins by trophoblasts (7), and by 
local maternal regulatory T cells (8) and produc-
tion of the immunosuppressive enzyme indole-
amine 2,3 dioxygenase (9).
A growing body of evidence now indicates 
that the adaptive immune response is regulated 
by the innate immune system; yet once engaged, 
adaptive immune responses can commandeer 
innate eff  ectors to induce injury. Indeed, some 
perturbations of innate immune responses are as-
sociated with “spontaneous” abortion. Comple-
ment activation, in particular, has emerged as a 
common event in recurrent pregnancy loss (10), 
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but whether it also contributes to abnormal placental 
  development is unknown. We have previously identifi  ed 
complement as a critical early eff  ector in antiphospholipid anti-
body-induced pregnancy loss and IUGR (11, 12). Although 
activation of complement and recruitment of infl  ammatory cells 
within decidual tissue are necessary intermediary steps in anti-
body-mediated pregnancy complications, the downstream 
pathogenic mediators of placental and fetal damage have not 
been defi  ned. It is likely that neutrophils and monocytes stimu-
lated by complement activation products directly damage the 
developing embryo. Alternatively, these armed eff  ector cells 
may release factors that cause placental dysfunction and com-
promise fetal growth, a mechanism that we investigated and re-
port on in this study.
Satisfactory development of the fetomaternal vasculature 
is required for successful embryonic growth, and insuffi   -
cient placental vascularization has been associated with early 
emb  ry  onic mortality, preeclampsia, and IUGR (13). Nor-
mal placental development requires coordinated expression of 
angiogenic growth factors, vascular endothelial growth factor 
(VEGF) and placenta growth factor, as well as expression of 
their respective receptors on invasive trophoblasts (14). VEGF 
promotes placental development and invasiveness primarily 
through interaction with the high-affi   nity type III receptor 
tyrosine kinases: VEGF receptor 1 (VEGFR-1, also known as 
Flt-1) and VEGFR-2 (15). Alternative splicing of VEGFR-1 
results in production of the secreted protein, soluble VEGFR-1 
(sVEGFR-1, also known as sFlt-1), which lacks the  cytoplasmic 
and transmembrane domains but retains the ligand-binding 
domain (16). The production of sVEGFR-1, a potent anti-
angiogenic molecule that sequesters circulating VEGF and 
placenta growth factor and prevents their interaction with en-
dogenous receptors (17), may be regulated independently of 
cell-bound VEGFR-1 (18, 19). Placental trophoblasts exposed 
to stress, such as hypoxia, release large amounts of sVEGFR-1 
into the maternal circulation (20). Excess sVEGFR-1 has been 
shown to inhibit placental cytotrophoblast diff  erentiation and 
invasion (21) and is thought to play a direct role in the patho-
genesis of abnormal placentation associated with preeclampsia 
and IUGR (14, 22, 23). Indeed, sVEGFR-1 levels have been 
shown to be increased in the placenta and blood of women 
with preeclampsia (for review see reference 14). Although 
considerable evidence indicates that proteins and receptors in 
the VEGF family are involved in the pathogenesis of placental 
disorders, the relationship between infl  ammation and dysreg-
ulation of angiogenic factors in pregnancy is unexplored.
A link between infl  ammation and angiogenesis has been 
established in the pathogenesis of other disease processes. In-
fl  ammatory mediators have been shown to stimulate resident 
cells to produce VEGF and promote angiogenesis and tissue 
damage: joint destruction in rheumatoid arthritis and choroi-
dal neovascularization in age-related macular degeneration 
(24–26). Under certain conditions, however, infl  ammatory 
cells may interrupt or prevent VEGF-induced angiogenesis 
by secreting sVEGR-1, which sequesters VEGF (18, 27). 
Given that functional VEGF defi  ciency leads to abnormal 
placental development, we considered the possibility that in-
fl  ammation at the maternal–fetal interface triggers sVEFGR-1 
production, leading to angiogenic factor imbalance and poor 
pregnancy outcomes.
Here we show that complement activation is a required 
intermediary event in the pathogenesis of fetal injury in an 
antibody-independent model of spontaneous miscarriage and 
IUGR, these pregnancy complications are associated with 
  elevated levels of the anti-angiogenic factor sVEGFR-1, and 
products of the complement cascade directly trigger release of 
sVEGFR-1 from monocytes. We provide the fi  rst evidence 
that complement activation alters the balance of angiogenic 
factors in pregnancy and identify a novel mechanism for 
  immune-triggered pregnancy complications.
RESULTS
Complement activation and infl  ammation 
at the maternal–fetal interface in CBA/J × DBA/2 matings
DBA/2-mated female CBA/J mice (CBA/J × DBA/2) are 
a well-studied model of immunologically mediated peri-
  implantation pregnancy loss that shares features with human 
recurrent miscarriage (28, 29). Embryos derived from mating 
CBA/J females with DBA/2 males showed an increased fre-
quency of resorption (29.4 ± 6.5%), more than three times 
greater than that seen within these and other strains or strain 
combinations (CBA/J × CBA/J: 8.9 ± 5.1%; CBA/J × 
BALB/c: 8.2 ± 5.6%; DBA/2 × DBA/2: 8.5 ± 6.6%; 
n  = 6–32 mice/group; CBA/J × DBA/2 vs. others, 
P < 0.01; Fig. 1 A). Embryonic lethality in DBA/2-mated 
female CBA/J mice is believed to represent rejection of the 
semiallogeneic placenta by maternal-derived activated eff  ec-
tors. Resorption is not universal, however, and surviving 
  fetuses show consistent and signifi   cant growth restriction. 
The average weight of fetuses from CBA/J × DBA/2  matings 
was nearly 30% lower than that of fetuses from the BALB/c-
mated female CBA/J mice (the control low abortion mating 
combination) at the same gestational age (212 ± 57 vs. 298 
± 42 mg, respectively; n  = 80–120 fetuses/group, 
P < 0.005). The phenotype of IUGR in CBA/J × DBA/2 
matings was homogenous: >95% of fetuses from DBA/2-
mated CBA/J mice weighed less than the average CBA/J × 
BALB/c product.
Given our fi   ndings that complement activation at the 
  fetal–maternal interface presents a danger to the developing 
fetus and that complement inhibition is an absolute require-
ment for normal pregnancy (11, 12), we hypothesized that 
excessive activation of complement contributes to fetal loss in 
CBA/J × DBA/2 matings. We conducted immunohistolog-
ical analyses of deciduas from days 5 to 15 of pregnancy. 
Staining with antibodies against mouse complement compo-
nent C3 showed extensive complement deposition on tro-
phoblast cells (Fig. 1 B), evident as early as day 6 in damaged 
embryos destined for resorption. Deposition of C3 in 
deciduas coincided with increased infi  ltration of infl  amma-
tory cells, which we identifi  ed as monocytes and neutrophils, 
and with the presence of necrosis and fetal debris (Fig. 1 D). JEM VOL. 203, September 4, 2006  2167 
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In contrast, in embryos from the same mating but with 
  normal morphology at day 6, we found that C3 staining was 
minimal and restricted to the ectoplacental cone, an area 
where C3 is present in normal pregnancies (7, 11). Similarly, 
in products of CBA/J × BALB/c matings examined from 
days 6 to 15, limited C3 staining was detectable, no infl  am-
mation was observed, and fetuses showed normal develop-
ment (Fig. 1, C and E).
Trophoblasts and embryos from CBA/J × DBA/2 mat-
ings had normal levels of complement receptor 1–related 
gene/protein y (Crry), the complement regulatory protein 
essential for pregnancy survival in mice (7). Expression of 
Crry, as detected by Western blotting of lysates from em-
bryos and deciduas of CBA/J × DBA/2 matings obtained 
from days 6 to 12, was comparable to that from CBA/J × 
BALB/c matings (ratio of arbitrary densitometry units: 1.03 ± 
0.06, n = 12 pairs). Hence, relative defi  ciency of Crry does 
not explain increased fetal resorption. Although we do not 
know which factors initiate the complement cascade, we 
consistently found decidual complement deposition and 
  extensive infl  ammation associated with embryonic death in 
products of CBA/J × DBA/2 pregnancies.
Inhibition of complement activation rescues pregnancies 
in CBA/J × DBA/2 matings
To provide direct evidence that complement activation is a 
critical mediator rather than a consequence of embryo injury 
in this model of spontaneous pregnancy loss, we attempted to 
rescue embryos of DBA/2-mated CBA/J mice with comple-
ment inhibitors. To block C3 activation by the alternative 
and classical pathways, and thereby prevent all downstream 
complement eff  ector activity, we treated pregnant mice with 
an inhibitor of C3 convertase, Crry-Ig (30). We and others 
have shown that Crry-Ig blocks complement activation 
in vitro and in vivo (11). We treated CBA/J × DBA/2 and 
CBA/J  × BALB/c mice with Crry-Ig or control mouse 
polyclonal IgG beginning at day 4 of pregnancy. That Crry-
Ig prevented pregnancy losses in DBA/2-mated CBA/J mice 
(Fig. 2 A) is proof of concept that complement is required for 
fetal loss and that its inhibition could off  er a target for therapy. 
Crry-Ig also protected surviving fetuses from IUGR (Fig. 
2 C), indicating that complement activation also contributes 
to growth failure in developing embryos.
Once the complement cascade is triggered, any of several 
complement activation fragment-derived ligand–receptor in-
teractions could mediate fetal injury and placental dysfunc-
tion. To defi  ne which elements of the complement pathway 
contribute to pregnancy complications, we focused on C5, a 
pivotal component of the cascade that generates two eff  ector 
pathways: C5a, a potent anaphylatoxin and cell activator, and 
C5b, which initiates formation of the C5b-9 membrane at-
tack complex. We treated DBA/2-mated CBA/J pregnant 
mice with an anti-C5 mAb that eff  ectively prevents C5 acti-
vation in vitro and in vivo (31). Blockade of C5 cleavage 
with anti-C5 mAb averted pregnancy loss and fetal growth 
restriction in CBA/J × DBA/2 matings (Fig. 2, A and C).
To distinguish the role of C5a and C5a receptor (C5aR) 
from that of membrane attack complex, we treated pregnant 
CBA/J × DBA/2 and control CBA/J × BALB/c matings 
with a highly specifi   c cyclic peptide antagonist of C5aR, 
AcPhe[l-ornithine-Pro-d-cyclohexylalanine-Trp-Arg], which 
possesses potent in vivo antiinfl  ammatory activity in mouse 
models of endotoxic shock and antiphospholipid syndrome 
(12, 32, 33). Administration of C5aR antagonist peptide 
  prevented both fetal resorption and IUGR in CBA/J × 
DBA/2 matings (Fig. 2, A and C) but had no eff  ect on the 
outcomes of CBA/J × BALB/c matings (Fig. 2, B and D). 
Protection conferred by the C5aR antagonist was comparable 
to that seen with anti-C5 mAb, suggesting that C5a–C5aR 
  interactions are important mediators in pregnancy damage in 
CBA/J  × DBA/2 matings. We cannot, however, exclude 
a role for C3a or C5b-9.
Immunohistological analysis of deciduas from CBA/J × 
DBA/2 mice treated with C5aR antagonist peptide showed 
Figure 1.  Resorption of embryos, deposition of complement C3, 
and infi  ltration of monocytes in decidual tissue of DBA/2-mated 
CBA mice. (A) Representative uteri from mice killed at day 15 of preg-
nancy are shown. The top panel, from a BALB/c-mated CBA/J mouse con-
tains larger amnion sacs and no resorptions. The bottom panel, from a 
DBA/2-mated CBA/J mouse, shows six amnion sacs of varying sizes and 
three resorptions (asterisks). (B–E) Pregnant mice were killed on day 8, 
and sections were stained with anti–mouse C3 (B and C) or anti–mouse 
F4/80 (D and E) to detect monocytes. In CBA/J × DBA/2 mice, there was 
extensive C3 deposition (brown, arrows; B) and monocyte infi  ltration 
(arrows) in the deciduas (D). In contrast, the decidual tissue from CBA/J × 
BALB/c mice showed minimal staining for C3 (C) and monocyte infi  ltra-
tion (E). e, embryo; ed, embryonic debris; md, maternal deciduas; t, troph-
oblasts; u, uterine wall. Bars, 0.1 mm.2168   COMPLEMENT INHIBITS PLACENTAL ANGIOGENIC FACTORS | Girardi et al.
minimal C3 deposition surrounding normal-appearing   fetuses 
and no evidence of infl  ammation, raising the possibility that 
recruited infl  ammatory cells amplify complement activation 
on trophoblasts and within decidua. Previous evidence indi-
cates that activated myeloid cells generate factor B and factor 
D (34). Indeed, cognate T cell–macrophage interactions are 
accompanied by alternative pathway activation (due to the 
production of C3, factor B, and factor D, as well as down-
regulation of complement regulatory protein expression) 
leading to the generation of C5a and the creation of a local 
amplifi  cation loop (35). Given the extensive infi  ltration of 
monocytes and neutrophils observed in the deciduas of CBA/
J × DBA/2 mice, we hypothesized that alternative pathway 
activation contributes to fetal injury. We treated CBA/J × 
DBA/2 and CBA/J × BALB/c mice with an anti–factor 
B mAb known to inhibit the alternative pathway in vitro and 
in vivo by blocking formation of the C3bBb complex (12, 
36). Fetal rejection and growth failure in CBA/J × DBA/2 
matings was prevented by anti–factor B mAb (Fig. 2, A and C), 
indicating that the alternative pathway plays a central role in 
initiating and/or amplifying injury.
In sum, our results show that factor B, C3, C5, and C5aR 
are required for pregnancy loss and growth restriction in an 
antibody-independent model of spontaneous miscarriage. 
We have previously shown that heparin inhibits complement 
activation in vivo and in vitro (37) and prevents pregnancy 
failure in antiphospholipid antibody-treated mice indepen-
dent of its anticoagulant eff  ects. Because some patients with 
recurrent miscarriage of undefi  ned etiology are treated with 
low-dose heparin, we examined the effi   cacy of this therapy in 
our mouse model of spontaneous miscarriage. We treated 
DBA/2-mated CBA/J females with sub-anticoagulant doses 
of heparin (10 U s.c. twice daily) beginning at day 4. As pre-
dicted by the results of experiments with complement inhib-
itors, the administration of low-dose heparin was eff  ective in 
preventing fetal resorptions (29.4 ± 6.5% vs. 7.9 ± 8.9%, 
P < 0.001). These results reemphasize the importance of 
complement in fetal damage and provide a framework for 
understanding how sub-anticoagulant doses of heparin exert 
benefi  cial eff  ects in miscarriage-prone pregnancies.
TNF-𝗂 in CBA/J × DBA/2 matings
Although we have implicated abnormal complement activa-
tion as a causative event in fetal loss and growth restriction, 
we have not addressed the relative contributions of comple-
ment as compared with other mechanisms. TNF-α regulates 
placental architecture, hormone synthesis, protease expres-
sion, and embryonic development (38). It is released when 
infi  ltrating infl  ammatory cells are activated by complement 
split products (39). Therefore, we considered the possibility 
that TNF-α contributes to pregnancy complications in DBA/
J-mated CBA/J mice. Elevated levels of TNF-α have been 
associated with miscarriage, placental oxidative stress, and 
preeclampsia (40) in human studies and with pregnancy fail-
ure in mice (39, 41). DBA/2-mated CBA/J mice showed in-
tense TNF-α staining of decidual tissue at day 7 and increased 
plasma TNF-α levels compared with CBA/J × BALB/c 
mice. Systemic TNF-α levels increased steadily from day 4 to 
day 10 of pregnancy (day 10: 325 ± 17 pg/ml) and remained 
elevated until day 15 (340 ± 35 pg/ml), when mice were 
killed. In contrast, plasma levels of TNF-α remained low and 
did not change during pregnancy in CBA/J × BALB/c mice 
(average level on days 1–15: 73 ± 9 pg/ml; CBA/J × DBA/2 
vs. CBA/J × BALB/c; n = 5–8 mice/group, P = 0.001). 
The increase in TNF-α observed in DBA/2-mated CBA/J 
females was prevented by inhibitors of complement activa-
tion, which we administered beginning on day 4. In CBA/J × 
DBA/2 mice treated with Crry-Ig or anti-C5 mAb, TNF-α 
levels did not increase (average levels on days 1–15: 94 ± 10 
and 88 ± 7 pg/ml, respectively; n = 6–7 mice/group) and 
were similar to those of CBA/J × BALB/c matings, suggest-
ing that the trigger for TNF-α production is downstream of 
complement activation.
Although elevated TNF-α levels induce trophoblast apop-
tosis and restrict trophoblast invasiveness (38, 42), phenotypes 
consistent with pregnancy failure we observed in CBA/J × 
DBA/2 mice, blockade of TNF-α with polyethylene glycol–
conjugated soluble TNF-α receptor type I (PEG sTNFRI) (39) 
did not rescue pregnancies (sTNFRI vs. control: 29.4 ± 6.5% 
Figure 2.  Inhibition of complement prevents fetal death and 
growth restriction in CBA/J × DBA/2 matings. DBA/2- and BALB/c-
mated CBA/J females were treated with recombinant Crry-Ig, anti-C5 
mAb (mAb BB5.1), C5aR antagonist peptide (C5aRAP) (AcPhe[L-ornithine-Pro-
D-cyclohexylalanine-Trp-Arg]), anti–factor B mAb (mAb 1379), or mouse 
polyclonal IgG (mIgG). Mice were killed on day 15 of pregnancy, uteri 
were dissected, embryos were weighed, and fetal resorption rates were 
calculated (number of resorptions/number of fetuses + number of 
resorptions). There were six to eight mice in each experimental group. 
(A and B) The frequency of fetal resorptions in treated and untreated 
CBA/J × DBA/2 and CBA/J × BALB/c pregnancies was determined 
(CBA/J × DBA/2 vs. CBA/J × BALB/c, P < 0.001; CBA/J × DBA/2 vs. 
CBA/J × DBA/2 plus   complement inhibitors; *, P < 0.001). (C and D) 
Average fetal weights in treated and untreated CBA/J × DBA/2 and 
CBA/J × BALB/c pregnancies was determined (CBA/J × DBA/2 vs. CBA/J × 
BALB/c, P < 0.005; CBA/J × DBA/2 vs. CBA/J ×DBA/2 plus complement 
inhibitors; *, P < 0.005).JEM VOL. 203, September 4, 2006  2169 
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fetal resorptions vs. 30.7 ± 7.8%). These fi  ndings indicate that 
although TNF-α may contribute to semiallogenic fetal rejec-
tion, it is not the exclusive eff  ector.
Angiogenic factors in CBA/J × DBA/2 matings
Given that proteins and receptors of the VEGF family are 
important for adequate placental development and that  fetuses 
from DBA/2-mated CBA/J mice die or show inadequate 
growth in utero, we considered the possibility that infl  amma-
tory mediators, and specifi  cally complement proteins, trigger 
dysregulation of angiogenic factors and produce placental 
dysfunction. We hypothesized that complement activation 
prevents VEGF signaling through cell-bound VEGFR and 
thereby leads to pregnancy complications in CBA/J × 
DBA/2 matings. To test this hypothesis, we measured free 
VEGF levels in plasma from days 1 through 15 of pregnancy. 
In CBA/J × BALB/c matings, free VEGF levels increased 
from days 2 to 5 and remained elevated throughout preg-
nancy (P < 0.001), whereas in DBA/2-mated CBA/J preg-
nancies, free VEGF did not increase above pre-pregnancy 
levels until day 12 (Fig. 3 A).
To determine whether production of VEGF in CBA/J × 
DBA/2 matings was defi   cient compared with CBA/J × 
BALB/c matings or whether VEGF was sequestered (and un-
detectable by ELISA) in CBA/J × DBA/2 matings, we ana-
lyzed total VEGF levels (unbound and sVEGFR-1–bound 
VEGF) in mouse plasma by immunoprecipitation with rabbit 
anti–mouse VEGF and Western blot. In contrast to free 
VEGF, total VEGF levels were comparable in abortion-prone 
and control matings, suggesting that circulating VEFG was 
bound in DBA/2-mated CBA/J mice and that the decrease 
in functional (unbound) VEGF is not due to changes in 
VEGF production (Fig. 3 B). Indeed, as early as day 4, plasma 
levels of the VEGF antagonist sVEGFR-1 were higher in 
CBA/J × DBA/2 matings than in controls (Fig. 3 C). Levels 
of sVEGFR-1 were signifi  cantly higher in CBA/J × DBA/2 
matings until day 12 (P < 0.001). These fi  ndings demon-
strate early dysregulation of angiogenic factors in abortion-
prone matings. Of note, the ELISA assay for sVEGFR-1 
measured bound and free sVEGFR-1, and increased VEGF 
was only detectable after day 12 of pregnancy, when 
sVEGFR-1 levels had fallen (Fig. 3). At this time, resorption 
of injured fetuses was complete and growth of surviving 
  fetuses was impaired.
To determine whether the anti-angiogenic state charac-
terized by excess sVEGFR-1 and defi  cient-free VEGF was 
associated with defective placental development, we exam-
ined placentas from viable fetuses on day 15 of pregnancy. 
The average weight of placentas from CBA/J × DBA/2 
matings was 24% lower than that from CBA/J × BALB/c 
pairs (84 ± 14 mg vs. 110 ± 17; n = 80–120 placentas/
group, P < 0.001), consistent with abnormal development. 
Because defects in trophoblast diff  erentiation and placental 
development limit embryonic growth, we performed histo-
logic analyses of midtrimester placentas from abortion-prone 
and control matings. We focused specifi  cally on trophoblast 
giant cells because they mediate implantation and invasion of 
the conceptus into maternal decidua of the uterus, and reduc-
tion in their number or abnormalities in their diff  erentiation 
Figure 3.  Dysregulation of angiogenic factors in CBA/J × DBA/2 
matings is prevented by inhibiting complement. Free VEGF, total 
VEGF, and sVEGFR-1 were assessed. Free VEGF (A) and total sVEGFR-1 
(C) levels in plasma were measured in CBA/J × DBA/2 (○) and CBA/J × 
BALB/c (●) mice from days 1 through 15 of pregnancy. Some DBA/2-
mated CBA/J mice were treated with Crry-IgG (◆), anti-C5 mAb (▲), 
and C5aR-AP (■). The arrows indicate the days when the complement 
inhibitors were administered. Values represent means from three to fi  ve 
mice/time point/group (free VEGF: CBA/J × DBA/2 vs. CBA/J × BALB/c, 
P < 0.001; CBA/J × DBA/2 vs. CBA/J × DBA/2 plus complement inhi-
bitors, P < 0.001; sVEGFR-1: CBA/J × DBA/2 vs. CBA/J × BALB/c, P < 
0.001; CBA/J × DBA/2 vs. CBA/J × DBA/2 plus complement inhibitors, 
P < 0.005). (B) Total VEGF levels were compared in CBA/J × BALB/c and 
CBA/J × DBA/2 matings. Plasma samples from early pregnancy (days 
5–8) and late pregnancy (days 9–12) were pooled into two groups for 
detection of total plasma VEGF (bound to sVEGFR-1 and unbound) by 
Western blotting. Samples were immunoprecipitated with rabbit anti–
mouse VEGF and analyzed with anti-VEGF mAb. Lane 1, CBA/J × BALB/c 
days 5–8; lane 2, CBA/J × BALB/c days 9–12; lane 3, CBA/J × DBA/2 
days 5–8; lane 4, CBA/J × DBA/2 days 9–12.2170   COMPLEMENT INHIBITS PLACENTAL ANGIOGENIC FACTORS | Girardi et al.
can cause placental defects and compromised pregnancies 
(43, 44). Placentas from CBA/J × DBA/2 matings showed a 
relative defi  ciency of trophoblast giant cells (Fig. 4, B, E and G) 
compared with those from CBA/J × BALB/c matings 
(Fig. 4, A and D), indicating abnormal trophoblast diff  erentia-
tion. We also observed impaired placental vascularization in 
CBA/J × DBA/2 matings with fewer fetal vessels invading 
the labyrinthine layer (not depicted). In contrast, placentas 
from CBA/J × DBA/2 matings treated with the comple-
ment inhibitor Crry-Ig showed no decrease in giant cells 
(Fig. 4, C, F and G); the histology was similar to that of 
CBA/J x BALB/c matings.
Although deposition of C3 and infi  ltration of infl  amma-
tory cells in placental tissue of viable, growth-restricted 
fetuses was only minimal, it is possible that elevated levels of 
sVEGFR-1 produced at sites of fetal resorption altered tro-
phoblast function in neighboring (otherwise normal) con-
cepti. Furthermore, abnormal placental development in such 
“innocent bystanders” could cause hypoxic stress in tropho-
blasts, stimulate release of more sVEGFR-1, and worsen the 
outcome of developing placentas and fetuses. The consistent 
decrease in placental and fetal weights in these surviving 
  fetuses of CBA/J × DBA/2 matings supports our concept 
that both a circulating inhibitor of placental development and 
local infl  ammatory injury cause placental failure.
To assess the eff  ect of complement activation on levels of 
angiogenic factors, we measured free VEGF and sVEGFR-1 
levels in CBA/J × DBA/2 matings treated with the comple-
ment inhibitors that protected pregnancies. If sVEGFR-1 is 
a critical eff  ector of fetal injury acting downstream of comple-
ment activation, we would not expect a sustained elevation of 
plasma sVEGFR-1 in mice treated with blockers of comple-
ment. In fact, inhibition of complement activation at the levels 
of C3 (Crry-Ig), C5 (anti-C5 mAb), or C5a–C5aR interac-
tions (C5aR antagonist) beginning on day 4 of pregnancy pre-
vented the increase in sVEGFR-1 (CBA/J × DBA/2 vs. 
CBA/J × DBA/2 plus complement inhibitors; P < 0.005) 
and associated decrease in free VEGF (P < 0.001; Fig. 3). 
Figure 4.  Decreased trophoblast giant cells in placentas from CBA/J × 
DBA/2 matings. (A–F) Histologic analysis of sections of uteri from CBA/J × 
BALB/c matings (A and D), CBA/J × DBA/2 (B and E) matings, and (C and F) 
CBA/J × DBA/2 matings treated with Crry-Ig killed at day 10 of pregnancy. 
Trophoblast giant cells (arrows) were reduced in midtrimester placentas from 
DBA/2-mated CBA/J pregnancies (B and E) compared with CBA/2 × BALB/c 
pregnancies, and this was prevented by treatment with Crry-Ig. Sections 
were stained with hematoxylin and eosin. e, embryo; lt, labyrinthine tropho-
blast u, uterine wall. Scale bars, 0.1 mm (A–C); 0.025 mm (D–F). (G) Number 
of trophoblast giant cells in placentas from days 10 and 11 of pregnancy was 
counted by light microscopy. Data are expressed as the mean of four sec-
tions counted by two readers blinded to experimental conditions. *, P < 0.01.JEM VOL. 203, September 4, 2006  2171 
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In contrast to the eff  ects of complement inhibitors, blocking 
TNF-α with sTNFRI, which does not improve pregnancy 
outcomes, failed to prevent the decrease in free VEGF 
(not depicted). Collectively, our data indicate that blockade of 
complement activation prevents the increase in sVEGFR-1, 
permits plasma levels of free VEGF to rise appropriately, and 
averts the fetal resorptions and growth restriction characteristic 
of CBA/J × DBA/2 pregnancies.
Complement activation triggers release of sVEGFR-1 
by monocytes in vitro
Because C3 deposition on decidual tissue and trophoblasts 
was associated with intense infi  ltration of monocytes (Fig. 1), 
because mononuclear phagocytes are essential eff  ectors  of 
damage in this model (28), and because peripheral blood 
mononuclear cells can express sVEGFR-1 (18, 27), we tested 
the hypothesis that complement activation products directly 
induce release of sVEGFR-1 by monocytes and thereby pro-
vide an additional (extra-placental) source of sVEGFR-1 to 
inhibit VEGF activity. To determine whether complement 
split products can trigger the production of sVEGFR-1, we 
incubated mouse splenic macrophages with immune com-
plexes (ICs; heat-aggregated human IgG) in the presence of 
10% mouse serum or heat-inactivated mouse serum. A heat-
labile serum factor activated by ICs induced a 10-fold in-
crease in secreted sVEGFR-1 (Fig. 5 A), consistent with a 
complement eff  ect. IC-mediated sVEGFR-1 production was 
not inhibited in the absence of stimulatory Fcγ receptors on 
macrophages, whereas the absence of serum C3 blocked the 
increase in sVEGFR-1, emphasizing that complement is the 
primary eff  ector. We could not detect free VEGF in superna-
tants from stimulated monocytes by ELISA, indicating that if 
VEGF is produced by IC-mediated activation of eff  ector 
cells, it is bound by excess sVEGFR-1 and unavailable to 
VEGF receptors expressed on trophoblasts and endothelial 
cells. Indeed, using Western blotting, which detects total 
VEGF (unbound and sVEGFR-1–bound), we did detect in-
creased VEGF in supernatants from complement-stimulated 
monocytes. Although complement activation products may 
stimulate VEGF release (25, 26), they also trigger monocytes 
to secrete sVEGFR-1, which sequesters VEGF.
To determine whether complement activation at the level 
of C3 or C5 is necessary to trigger release of anti-angiogenic 
factors associated with adverse pregnancy outcomes, we per-
formed experiments using serum defi  cient in C5. Production 
of sVEGFR-1 was similar in macrophages stimulated with IC 
in C3- or C5-defi  cient serum, indicating that C5 activation 
products, rather than C3a, were required. Indeed, stimulation 
with synthetic C5a induced sVEGFR-1 production, whereas 
C5aR-defi  cicent macrophages did not increase sVEGFR-1 
release after stimulation with IC in the presence of serum (Fig. 
5 A), arguing against a critical role for C3aR as a trigger for 
sVEGFR-1, although some contribution cannot be excluded. 
Furthermore, we found that C5a induced sVEGFR-1 release 
directly, rather than acting through TNF-α. A role for TNF-α 
was plausible because it is rapidly released by C5a-stimulated 
monocytes and is known to infl  uence production of angio-
genic factors (45). Incubation of monocytes with TNF-α at 
2 ng/ml (a concentration sevenfold higher than peak levels 
measured in DBA/2-mated CBA/J females) did not stimulate 
increased sVEGFR-1 production (Fig. 5 A), consistent with 
our fi  ndings that TNF-α blockade did not prevent fetal loss in 
CBA/J × DBA/2 pregnancies, whereas complement block-
ade was protective. Collectively, these results support our in 
vivo fi   ndings that complement activation, and specifi  cally 
C5a–C5aR interactions, induce infi  ltrating monocytes to pro-
duce sVEGFR-1, and that sVEGFR-1 then binds VEGF and 
inhibits its activity during placental development.
Figure 5.  Complement activation triggers release of sVEGFR-1 
by murine macrophages and human monocytes in vitro. (A) Splenic 
macrophages from CBA/J female mice were stimulated with heat-
  aggregated human IgG (IC) in the presence of 10% normal mouse serum, 
10% heat-inactivated mouse serum (HIS), 10% serum from C3-defi  cient 
mice (C3−/−), or 10% serum from C5-defi  cient mice (C5−/−). Macrophages 
were also incubated with C5a, TNF-α, or control medium. Splenic macro-
phages from mice defi  cient in stimulatory Fcγ receptors (FcRγ−/−) or 
C5aR (C5aR−/−) were also treated with ICs. Culture supernatants were 
collected after 24 h and analyzed for sVEGFR-1 by ELISA (n = 3–9 
  experiments/group; *, P < 0.001 vs. control). (B) Adherent human 
  mononuclear cells from healthy donors were stimulated with ICs plus 
10% normal human serum and ICs plus 10% heat-inactivated human 
serum, C5a, or TNF-α. After 2 h, culture supernatants were collected 
and analyzed for sVEGFR-1 by ELISA (n = 4–5 experiments/group; *, 
P < 0.005 vs. control).2172   COMPLEMENT INHIBITS PLACENTAL ANGIOGENIC FACTORS | Girardi et al.
To determine whether similar mechanisms may be oper-
ative in patients, we incubated human peripheral monocytes 
with ICs in the presence of 10% human serum, heat-inacti-
vated serum, or synthetic C5a. Similar to our fi  ndings in 
mouse macrophages, ICs induced a sixfold increase in 
sVEGFR-1 in supernatants, an eff  ect that was blocked by 
heat inactivation of serum (Fig. 5 B). Here too, synthetic C5a 
was a potent stimulus for sVEGFR-1 production, whereas 
TNF-α had no eff  ect.
DISCUSSION
The experiments we report in this study provide the fi  rst evi-
dence linking the complement system to angiogenic factor 
imbalance associated with placental dysfunction. Our in vitro 
fi  nding that complement activation products, and in parti-
cular C5a, stimulate monocytes to produce sVEGFR-1, 
which sequesters VEGF, confi  rms our in vivo experiments 
with complement inhibitors (Fig. 3). Collectively, these stud-
ies provide defi  nitive proof that the complement system reg-
ulates VEGF activity and imply that defi  ciency of free VEGF 
induced by high levels of sVEGFR-1 leads to abnormal pla-
cental development (Fig. 4) and causes fetal growth restric-
tion or death (Fig. 2).
Our fi  ndings that complement is activated at the mater-
nal–fetal interface (Fig. 1) and that inhibition of complement 
activation rescues pregnancies (Fig. 2) and reverses angio-
genic imbalance in CBA/J × DBA/2 matings (Fig. 3) dem-
onstrate that complement has an essential and causative role 
in damage to the fetal–placental unit. Previous studies have 
implicated the complement pathway in pregnancy failure 
(6, 9–12), but this study is the fi  rst to show that local comple-
ment activation not only causes fetal death, but also leads to 
abnormal placental development. Although the triggers of 
immune dysregulation and complement activation in CBA/
2-mated CBA/J mice remain unknown, the fi  nding  that 
  factor B, C5, and C5aR are required to produce fetal injury 
in this autoantibody-independent disease model identifi  es 
specifi  c elements in the complement pathway as potential 
targets for interventions to prevent recurrent pregnancy com-
plications in patients.
Two features of the developing placenta provide an 
  environment conducive to complement activation: relative 
hypoxia and the presence of externalized phosphatidylserine 
on the outer leafl  ets of trophoblasts (13, 46, 47). In this 
  hypoxic milieu, natural antibodies that recognize neoepit-
opes and/or negatively charged phospholipids may initiate 
the complement cascade via the classical pathway, as has 
been described in experimental models of intestinal ische-
mia-reperfusion injury (48). The alternative pathway, acti-
vated independently of antibodies and the predominant 
initiator of damage in renal ischemia (36, 48), may also initi-
ate the complement cascade and contribute to fetal damage 
in our model because anti–factor B mAb prevented fetal 
growth restriction and death in DBA/2-mated CBA/J mice. 
Our fi  ndings do not exclude a contribution of the lectin–
complement pathway (49, 50).
Inappropriate activation of the alternative pathway has 
also been implicated in mouse studies of pregnancy loss in-
duced by antiphospholipid antibodies, activated maternal 
T cells, and defi  cient trophoblast expression of the comple-
ment inhibitor Crry (9, 12, 51), although the specifi  c triggers 
that initiate the complement cascade are still unclear. Failure 
of mechanisms that normally protect the fetus from the ma-
ternal immune response, be they cellular or humoral, may 
lead to fetal injury, and the resulting damaged and dying 
(apoptotic and necrotic) cells can initiate the complement 
cascade. Potential mechanisms to amplify complement acti-
vation via the alternative pathway include increased synthesis 
of alternative pathway components by endogenous cells or by 
infi  ltrating infl  ammatory cells, and decreased expression of 
complement regulatory proteins. Further studies are neces-
sary to identify the initiators of complement activation in 
complicated pregnancies and to establish whether any of 
these potential mechanisms are operative in patients.
In this study, we present the fi  rst evidence that mono-
cytes exposed to complement activation products are stimu-
lated to produce sVEGFR-1, a potent inhibitor of VEGF 
activity. Although trophoblasts and endothelial cells have 
been shown to produce sVEGFR-1, our work emphasizes 
the importance of infi  ltrating monocytes as proximate medi-
ators of damage, fi  ndings consistent with evidence that deple-
tion of monocytes or blockade of ICAM-1–LFA interactions 
prevents abortion in DBA/2-mated CBA/J mice (28, 29). 
That blockade of C5a–C5aR interactions prevents increased 
sVEGFR-1 release while murine trophoblasts lack C5a re-
ceptors (not depicted) also indicates that activated leukocytes 
are the source of excess sVEGFR-1.
Our fi  ndings stand in contrast with the recent reports of 
enhanced angiogenesis by complement components C3a and 
C5a. We found that monocytes recruited and activated by 
complement split products at the maternal–fetal interface re-
lease suffi   cient sVEGFR-1 to inhibit the increasing amounts 
of VEGF produced by the placenta, whereas in experimental 
models of arthritis and age-related macular degeneration, ICs 
and complement activation products induce release of VEGF 
and cause neovascularization (24–26). The primary source of 
VEGF in these models is resident synovial cells and retinal 
cells, respectively, although recruited leukocytes have also 
been shown to release VEGF in response to complement ac-
tivation. It appears that under diff  erent conditions monocytes 
have diff  erent responses to complement activation products. 
Future studies can address whether the pathway of monocyte 
activation (Th1- vs. Th2-type cytokines; innate vs. acquired 
immune activation; reference 52) infl  uences the balance be-
tween secretion of angiogenic and anti-angiogenic factors in 
response to a given stimulus.
By implicating infl  ammatory cells (recruited and activated 
by complement split products) as a source of inhibitors of 
  angiogenesis, we have identifi  ed a new mechanism by which 
immune activation, long believed to be a contributor to 
pregnancy failure, may cause recurrent abortion and fetal 
growth restriction. Our fi  ndings emphasize the central role of JEM VOL. 203, September 4, 2006  2173 
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complement proteins as key innate immune eff  ectors that 
mediate poor pregnancy outcomes. The link between com-
plement activation and the balance of angiogenic and anti-
angiogenic factors, beyond its importance in pregnancy loss 
and IUGR, also has direct implications for understanding 
  immune mechanisms in preeclampsia, ischemic injury, and 
tumor survival.
MATERIALS AND METHODS
Mice. Inbred CBA/J (H-2k), DBA/2 (H-2d), C3−/−, and C5−/− male and 
female mice were obtained from The Jackson Laboratory. BALB/c males 
were obtained from Taconic Farms. FcRγ-defi  cient mice backcrossed to 
BALB/c mice were provided by J. Ravetch (The Rockefeller University, 
New York, NY; reference 53). C5aR-defi   cient mice on a BALB/c 
  background were provided by C. Gerard (Harvard Medical School, Boston, 
MA; reference 54).
Mice matings and treatment protocols. 8–10-wk-old virgin female 
CBA/J mice were mated with 8–14-wk-old CBA/J, BALB/c, or DBA/2 
males. Females were inspected daily for vaginal plugs, and presence of a vagi-
nal plug was designated as day 0 of pregnancy. Pregnant females were killed 
at predetermined intervals (from days 6 to 15). The frequency of fetal resorp-
tion was calculated on day 15 (number of resorptions/total number of 
formed fetuses and resorptions). Resorption sites are easily identifi  ed and 
  result from loss of a previously viable fetus. Weights of fetuses and placentas 
were also determined.
To inhibit C3 convertase, pregnant mice were injected i.p. on days 
4, 6, and 8 of pregnancy with 3 mg of recombinant Crry-Ig, a soluble chi-
meric protein that contains the fi  ve extracytoplasmic short consensus repeat 
domains of Crry linked to the hinge and CH2 and CH3 domains of the 
noncomplement fi  xing mouse IgG1 isotype (30). To block C5 cleavage, 
mice were treated with anti-C5 mAb (1 mg i.p.; mAb BB5.1) on days 4 
and 6 (31). To block C5a–C5aR interactions, mice received a C5aR cyclic 
antagonist peptide (50 μg i.p.; AcPhe[l-ornithine-Pro-d-cyclohexylalanine-
Trp-Arg]) on day 4 (12, 32). Alternative pathway activation was inhibited by 
administering anti–factor B mAb (2 mg i.p.) on days 4–10 of pregnancy (36). 
For each complement inhibitor study, a group of mice treated with mouse 
IgG at the same doses and schedule of administration as those of the recom-
binant protein or mAbs served as the control. To study the eff  ects of heparin, 
we treated mice with unfractionated heparin (10 U s.c., twice per day) from 
days 4 to 8. At this dose of heparin, we did not detect an increase in partial 
thromboplastin time values compared with untreated mice (32 ± 2 s vs. 
29 ± 2 s). To inhibit TNF-α, pregnant mice were treated with PEG sTNFRI 
(5 mg/kg, i.p.; Amgen Inc.) on days 2, 4, and 6 of pregnancy.
Complement deposition and cellular infi  ltration were analyzed on de-
cidual tissue at diff  erent points in pregnancy. Plasma samples were obtained 
from pregnant females from days 1 to 15 of pregnancy. TNF-α was mea-
sured using the OptEIA kit (BD Biosciences). VEGF and sVEGFR-1 levels 
were measured in plasma samples using ELISA methods (R&D Systems). 
The ELISA for VEGF detects only free (unbound) VEGF and that for 
sVEGFR-1 measures total sVEGFR-1 (VEGF-bound and unbound). Proce-
dures that involved mice were approved by the Institutional Animal Care 
and Use Committee of the Hospital for Special Surgery and were conducted 
in strict accordance with guidelines for the care and use of laboratory   research 
animals promulgated by the National Institutes of Health (NIH).
Immunohistochemistry. Uteri removed at diff   erent points during 
  ges  tation were frozen in O.C.T. compound, and 10-μm-thick sections of 
  embryos and placentas were cut. Sections were incubated with goat anti–
mouse C3 (Cappel), goat anti–mouse TNF-α (R&D Systems), or rat anti–
mouse F4/80 (Serotec) mAbs, followed by incubation with specifi  c secondary 
IgG antibodies conjugated with horseradish peroxidase (HRP; BD Biosci-
ences). Bound IgG-HRP was detected with diaminobenzidine. Sections 
were counterstained with hematoxylin or methyl green. Sections of frozen 
tissue were also stained with hematoxylin and eosin. The number of tropho-
blast giant cells in midtrimester placentas was counted using light microscopy 
by two diff  erent observers blinded to the experimental conditions. Values 
presented represent means ± SD from eight diff  erent sections from the 
  central portion of embryos for each condition and time.
Western blot analysis. Uterine contents (fetal–placental unit) were 
  removed from mice on days 7–12 of pregnancy and immediately frozen 
at −70°C. The tissue was homogenized and lysates were resolved by electro-
phoresis and transferred to a nitrocellulose membrane as described previously 
(12). Membranes were probed with HRP-conjugated goat anti–mouse Crry 
(Sigma-Aldrich) and visualized using a chemiluminescence detection kit 
(Amersham Life Science), and autoradiograms were analyzed by densitometry. 
To measure total VEGF (unbound and bound to sVEGFR-1) in mouse 
plasma, samples were immunoprecipitated with rabbit anti–mouse VEGF 
(Antigenix America), analyzed with goat anti–rat VEGF antibody (R&D 
Systems), and probed with rabbit anti–goat HRP (BD Biosciences).
Production of sVEGFR-1 in vitro. Splenocytes from female mice were 
incubated for 2 h in culture medium supplemented with 10% inactivated 
FCS. Nonadherent cells were removed, and adherent cells (>95% peroxi-
dase-positive) were incubated in culture medium supplemented with 10% 
inactivated fetal bovine serum with the addition of the following stimuli: 
none (control); 200 μg/ml of heat-aggregated human IgG (ICs) plus 10% 
normal mouse serum; ICs plus 10% heat-inactivated mouse serum; 10 nM 
C5a; ICs plus 10% serum from C3-defi  cient mice; ICs plus 10% serum from 
C5-defi  cient mice; and 2 ng/ml TNF-α. Human peripheral blood mono-
cytes purifi  ed by Ficoll density centrifugation and adherence (>95% peroxi-
dase-positive) were stimulated with 200 μg/ml ICs plus 10% normal human 
serum and ICs plus 10% heat-inactivated human serum, 10 nM C5a, or 
2 ng/ml TNF-α. After 2 h, culture supernatants were collected and analyzed 
for sVEGFR-1 by ELISA (R&D Systems).
Statistical analysis. Data are expressed as mean ± SD. After it was deter-
mined that the data were normally distributed (Kolomogorov-Smirnov test 
of normalcy), the Student’s t test (two-tailed) was used to compare fetal 
  resorption frequencies and fetal weights between groups. Kruskal-Wallis 
ANOVA was used to compare patterns of angiogenic factor levels or TNF-α 
levels in diff  erent mating pairs and groups of mice receiving diff  erent treat-
ments through pregnancy. A probability of <0.05 was used to reject the 
null hypothesis.
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